SOCIUM Inc. signs an agreement with Suzhou Brainlight Biomedical Technology Co., Ltd

SOCIUM Inc. (Head Office: Chuo-ku, Tokyo; President: Katsuhisa Horimoto)[#1] has signed a cooperative agreement with Suzhou Brainlight Biomedical Technology Co., Ltd (苏州铂莱特医药科技有限公司).

The three key points of the cooperative agreement are the following three projects

・Phosphorylation array analysis service business (#2)
・Therapeutic drug seeds discovery and development projects (#3)
・In particular, projects to conduct investigator-initiated clinical trials for therapeutic drug seeds (#4)

Suzhou Brainlight Biomedical Technology Co., Ltd is a drug discovery venture started by young researchers with Prof. Dongyin Chen (陈冬寅) of School of Pharmacy, Nanjing Medical University as president. Through this collaboration, by combining our drug repositioning technology for discovering therapeutic drug seeds and Suzhou Brainlight Biomedical Technology’s compound synthesis development technology/efficacy verification technology, we will strategically and quickly discover highly accurate therapeutic drug seeds based on the existing drug structure.
Furthermore, investigator-initiated clinical trials will be conducted in a group of hospitals affiliated with the Chinese universities to obtain a human PoC for the discovered therapeutic seeds as soon as possible. Through this drug discovery ecosystem consisting of collaboration between the Japanese and Chinese drug discovery ventures and the big hospitals in China, we will accelerate the development of new drugs. Please stay tuned for further developments.

#1 SOCIUM Inc. is a venture company that uses drug repositioning technology to discover drug discovery seeds, especially drug candidates for rare diseases. With the vision of ” Medicine to patients with diseases for which there is no medicine, and Medicine to patients with diseases for which there is no effective medicine”, we are working to overcome the unmet medical needs of patients. Our Chinese name is 舒胜药物开发股份有限公司.
#2 Phosphorylation Analysis System, “Phospho-Totum” (Patent #6884389), is the world’s first system that seamlessly integrates comprehensive measurement and data analysis of phosphorylation state in cells. Unlike conventional measurements in an artificial environment, the system uses cell lysate as a sample to achieve measurement in a more mimic state of the cell. The protein arrays developed by our company are used to measure the phosphorylation levels of 1,471 different whole proteins (substrates) in the sample. From the measured values, the system estimates the condition-specific phosphorylated substrates, the activation levels of 273 signaling pathways, and the activation levels of 185 kinases (tyrosine kinase and serine/threonine kinase), and also estimates the target kinase of the drug candidate.
#3 Please refer to the relevant point on our website (https://socium.co.jp/drug_discovery/) for information on our proprietary drug discovery approach and its results.
#4 Our first therapeutic drug development is an investigator-initiated clinical trial for a potential treatment for Amyotrophic Lateral Sclerosis (ALS) at Huaxi Hospital of Sichuan University (Principal Investigator: Prof. Huifang Shang (商慧芳)). (https://socium.co.jp/2024/09/17/2024091701/;　https://socium.co.jp/2025/04/15/2025041501en/). We are currently preparing for our second investigator-initiated clinical trial for the development of a therapeutic drug with金庆文医師, Prof. of Nanjing Medical University Sir Run Run Hospital, as the principal investigator.

For inquiries regarding this matter, please contact
SOCIUM Inc.
5th, 6th, and 7th floors of Waterfront Center Annex, National Institute of Advanced Industrial Science and Technology (AIST)
2-4-7 Aomi, Koto-ku, Tokyo, Japan 1350064
https://socium.co.jp
E-mail: contact@socium.co.jp